Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2022-05-12 Interim / Quarterly Rep…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 10-Q for the quarter ended March 31, 2022
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q filed with the U.S. Securities and Exchange Commission by Oramed Pharmaceuticals Inc. It explicitly states it is a 'Quarterly Report' for the period ended March 31, 2022, and contains interim condensed consolidated financial statements, management's discussion and analysis, and other required disclosures. This fits the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-12 English
Form 10-Q for the quarter ended March 31, 2022
Report Publication Announcement Classification · 100% confidence The document is a short notification (approx. 2000 characters) filed with the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Quarterly Report on Form 10-Q' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, this is an announcement of a report publication rather than the report itself. Therefore, it is classified as a Report Publication Announcement (RPA). Q1 2022
2022-05-12 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2022
2022-05-12 English
Form 4A -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Arie Mayer
Director's Dealing Classification · 100% confidence The document explicitly states 'FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION' and 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP'. Form 4 is the standard SEC filing used to report insider transactions (changes in beneficial ownership) by directors, officers, or 10% owners of a company's stock. This directly corresponds to the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). Although the document is an amendment to a previous filing, its core purpose remains the reporting of insider transactions.
2022-05-10 English
Form 4A -STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Arie Mayer
Regulatory Filings Classification · 95% confidence The document is a filing from ORAMED PHARMACEUTICALS INC, reported via MAGNA to the Israel Securities Authority and Tel Aviv Stock Exchange. It explicitly states: "Attached hereto is a report on *Form 4A - Arie Mayer*" followed by a PDF filename. Form 4A filings in this context, especially when referencing director/officer names (Arie Mayer) and being short (1887 chars), strongly suggest a report detailing insider transactions or changes related to management/directors. Since the document itself is an announcement attaching the actual report (Form 4A), and Form 4A often relates to insider trading or director dealings, the most fitting category is Director's Dealing (DIRS). If it were a general announcement of a report publication without specifying the content type, RPA would be considered, but the content points specifically to insider activity.
2022-05-10 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP-Arie Mayer
Director's Dealing Classification · 99% confidence The document text explicitly contains the header "FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION" and the title "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP". Form 4 is the standard SEC filing used to report insider transactions (changes in beneficial ownership) by directors, officers, and 10% owners of a company's stock. This directly corresponds to the definition of Director's Dealing (insider trades). Although the document describes transactions by a Director ('Mayer Arie'), the specific SEC form dictates the classification. The closest matching category is 'Director's Dealing' (DIRS). It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), as it is a highly specific insider transaction report.
2022-05-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.